Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection

Satoru Hagiwara; Naoshi Nishida; Hiroshi Ida; Kazuomi Ueshima; Yasunori Minami; Masahiro Takita; Tomoko Aoki; Masahiro Morita; Hirokazu Chishina; Yoriaki Komeda; Akihiro Yoshida; Hidetoshi Hayashi; Kazuhiko Nakagawa; Masatoshi Kudo

doi:10.1111/hepr.13798

Abstract

1 min read

In rare cases, HBsAg-positive patients may be reactivated by ICI administration. On the other hand, when ICI is administered, it is expected to have an antiviral effect on HBV due to its immune tolerance inhibitory effect, and future drug development is expected.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Letter2011

Smoking, Hepatitis B Virus Infection, and Development of Hepatocellular Carcinoma

Morris Sherman, Josep M. Llovet

JNCI Journal of the National Cancer Institute

Article2021

Nephrotoxicity in patients with cancer treated with immune checkpoint inhibitors.

Evangelos Eleutherakis Papaiakovou, Efstathios Kastritis, Flora Zagouri, Dimitra Grapsa, Ioannis Ntanassis-Stathopoulos, Dimitra Stefanou, George Evangelou, Ilias Kotteas, Meletios A Dimopoulos, Konstantinos Syrigos

Article2014

Clinical Features of Vascular Disorders Associated with Chronic Hepatitis Virus Infection

Naoshi Nishida, Masatoshi Kudo

Article2014

Multicenter observational study of reactivation of hepatitis B virus (HBV) caused by chemotherapy for solid tumors (ST).

Shunsuke Kondo, Masafumi Ikeda, Masatoshi Kudo, Seijin Nadano, Junji Furuse, Yukio Osaki, Takashi Kumada, Kazuyoshi Ohkawa, Masashi Mizokami

Article2000

Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L‐FMAU, DAPD, penciclovir and lobucavir

Ying Ying, De Clercq Erik, Nicholson Nicholson, Furman, Johan Neyts